---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-25-000004"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:31:13.121672+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio restructures: cuts 65% workforce, shifts focus to celiac VTP-1000

## Summary
- Workforce reduction of ~65%; plans to close UK site, consolidate operations in Germantown, MD.
- CFO Gemma Brown (departing April 30, 2025) and COO Graham Griffiths (June 30, 2025) to leave; severance agreements anticipated.
- Prioritizes VTP-1000 (celiac disease) with Phase 1 data expected mid-2025; postpones VTP-300 hepatitis B development until partner found.
- Preliminary cash, cash equivalents and restricted cash of $112M as of Dec 31, 2024; cash runway extended to start 2027.
- Key 2025 milestones: VTP-1000 SAD data mid-2025; HBV003 and IM-PROVE II results in Q2 2025; VTP-850 prostate cancer data Q2 2025.

## SEC filing metadata
- accession: 0001828185-25-000004
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000004/0001828185-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000004/brns-20250110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-25-000004
- JSON: https://secwatch.observer/filing/0001828185-25-000004.json
- Plain text: https://secwatch.observer/filing/0001828185-25-000004.txt

## Key facts
- Executive change
  Gemma Brown was terminated as Chief Financial Officer at Barinthus Biotherapeutics plc..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: the employment of Gemma Brown effective as of April 30, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000004/0001828185-25-000004-index.htm
- Executive change
  Graham Griffiths was terminated as Chief Operating Officer at Barinthus Biotherapeutics plc..
  - Action: terminated
  - Role: Chief Operating Officer
  source text: the Company will terminate the employment of Graham Griffiths effective as of June 30, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000004/0001828185-25-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.